Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up

Bonroy, Carolien; Piette, Yves; Allenbach, Yves; Bossuyt, Xavier; Damoiseaux, Jan

doi:10.1016/j.jtauto.2022.100148

Cited by 5 publications

(4 citation statements)

References 77 publications

(133 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, inflammatory myopathy is classified based on these myositis-specific autoantibodies because each group has unique characteristics [ 3 ], and anti-synthetase syndrome is a new concept to be a differentiated nosological disease from DM. [ 4 ] For example, patients with MDA-5 antibody-positive DM (MDA-5-DM) often present with clinically amyopathic DM (CADM), which is frequently complicated by rapidly progressive interstitial lung disease (ILD) and have a bad prognosis [ 5 ]. Alternatively, anti-TIF-1γ antibody-positive DM is closely associated with cancer-associated DM, and patients present with skin rashes, proximal muscle weakness, and dysphagia [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy

Harada

Tominaga

Iitoh

et al. 2022

JCM

View full text Add to dashboard Cite

We retrospectively analyzed the clinical and laboratory data of patients diagnosed with anti-transcriptional intermediary factor 1 (TIF-1γ) antibody-positive polymyositis (PM)/dermatomyositis (DM) to clarify the characteristics of this disease. We identified 14 patients with TIF-1γ antibody-positive DM (TIF-1γ DM), 47 with anti-aminoacyl-tRNA synthetase antibody (ARS)-positive PM/DM, and 24 with anti-melanoma differentiation-associated gene 5 antibody (MDA-5)-positive PM/DM treated at the Kurume University Hospital between 2002 and 2020. Patients with TIF-1γ DM were significantly older than the other two groups. Nine patients with TIF-1γ DM were female, thirteen patients had DM, and one had clinically amyopathic DM. Primary malignant lesions were lung (3), uterus (2), colon (2), breast (2), ovary (1), lymphoma (1), and unknown (2). Cutaneous manifestation and dysphagia were the most common symptoms in TIF-1γ DM. Erythema (9/14), the V-neck sign (8/14), heliotrope (9/14), and nailfold telangiectasia (14/14) were significantly more common in TIF-1γ DM. Furthermore, no patients with TIF-1γ DM had interstitial lung abnormality on high-resolution CT. In patients with TIF-1γ DM, the frequency of dysphagia and unusual erythema, particularly that which spreads from the trunk, and nailfold telangiectasia, were characteristic findings. In most patients with TIF-1γ DM, it is necessary to administer other immunosuppressive drugs along with glucocorticoids.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy

Harada

Tominaga

Iitoh

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…В последнее время при данной патологии отмечен взрывной рост числа выявляемых антител, среди которых выделяют миозит-специфические антитела (МС-АТ) и миозит-ассоциированные антитела (МА-АТ) [6][7][8][9]. Существует более 15 специфических антител, участвующих в патогенезе аутоиммунной некротизирующей миопатии [4,[7][8][9]. МА-АТ имеют менее выраженную специфичность и часто обнаруживаются при других системных аутоиммунных ревматических болезнях.…”

Section: диагностика и лечение статин-индуцированной некротизирующей ...unclassified

“…При СИНАМ в крови определяются анти-HMGCR и анти-SRP, хотя они могут и отсутствовать. Соответственно, выделяют три серологических варианта заболевания: анти-HMGCR-позитивный, анти-SRP-позитивный и серонегативный [6,8,9,[16][17][18][19]. Титр анти-HMGCR коррелирует с тяжестью проявлений болезни [16].…”

Section: клиническая картинаunclassified

“…Тем не менее, результаты серологического исследования позволяют окончательно подтвердить диагноз СИНАМ. Для лабораторной серологической диагностики аутоиммунных миопатий целесообразно использовать панели, включающие в себя несколько типов аутоантител [9].…”

Section: клиническая картинаunclassified

See 1 more Smart Citation

Diagnosis and treatment of statin-induced necrotizing autoimmune myopathy

Sumarokov¹,

Ezhov²

2022

CPT

View full text Add to dashboard Cite

Statin-induced necrotizing autoimmune myopathy (SINAM) is an exceptionally rare complication of statin therapy. SINAM belongs to the group of idiopathic inflammatory myopathies and is characterized by muscle cell necrosis and regeneration leading to muscle atrophy. Prominent lymphocytic infiltrates in muscle tissue are absent. Progressive muscle weakness in upper and lower extremities is the main clinical manifestation of SINAM. Autoimmune mechanism of pathogenesis explain the absense of therapeutic effect of statin discontinuation and the risk of relapses. Diagnosis of SINAM can be established by clinical and serologic data, muscle biopsy and the results on noninvasive methods (MRI, ultrasound). Early initiation of immunosuppressive treatment is essential to achieve the cure of SINAM.

show abstract

256th ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021

Allenbach

Benveniste

Bonroy³

et al. 2022

Neuromuscular Disorders

View full text Add to dashboard Cite

Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up

Cited by 5 publications

References 77 publications

Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy

Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy

Diagnosis and treatment of statin-induced necrotizing autoimmune myopathy

256th ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021

Contact Info

Product

Resources

About